pde-2 Antibody

Definition and Target Specificity

PDE2A antibody is a specialized immunological reagent designed to detect and quantify phosphodiesterase 2A (PDE2A), a dual-specificity enzyme that hydrolyzes cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), critical second messengers in cellular signaling . PDE2A antibodies are essential for studying PDE2A’s expression, localization, and function in physiological and pathological contexts, including cancer, cardiovascular diseases, and neurological disorders .

Cancer Biology

• Growth and Invasion: PDE2A promotes melanoma cell proliferation and invasion by modulating cAMP-protein kinase A (PKA) signaling. Silencing PDE2A with siRNA reduces tumor cell growth and metastatic potential .

• Therapeutic Targeting: Selective PDE2 inhibitors (e.g., EHNA) elevate intracellular cAMP, suppressing tumor progression .

Neuroprotection and Inflammation

• Cerebral Ischemia: PDE2 inhibition (via Bay-607550) reduces apoptosis and inflammation in brain ischemia-reperfusion injury by enhancing PKA activity .

• Alzheimer’s Disease: PDE2 inhibitors (e.g., BAY 60-7550) reverse amyloid-β-induced memory deficits by restoring cGMP/PKG signaling and neuronal survival pathways .

Cardiovascular Regulation

• Heart Failure: PDE2 inhibition improves cardiac contractility and reverses pathological remodeling in pressure-overload heart failure models .

• cGMP/cAMP Crosstalk: PDE2 regulates cardiomyocyte Ca²⁺ handling and contractility by balancing cAMP and cGMP levels .

Experimental Validation

• Western Blot: Detects PDE2A at ~105 kDa in brain, heart, and kidney tissues .

• Immunohistochemistry: Localizes PDE2A in endothelial cells (cardiac/renal tissues) and tumor microenvironments .

Signaling Pathways

• cAMP-PKA Axis: PDE2A inhibition elevates cAMP, activating PKA to suppress pro-inflammatory cytokines (e.g., IL-17, IL-22) and apoptosis markers (Bax/Bcl-2 ratio) .

• cGMP-PKG Axis: Enhanced cGMP signaling via PDE2A blockade improves synaptic plasticity and cognitive function in neurodegenerative models .

Pharmacological Modulation

• Small-Molecule Inhibitors: BAY 60-7550 (PDE2 inhibitor) reduces infarct size by 40% in cerebral ischemia models .

• EC₅₀ Values: Selectivity profiles of PDE2 activators (e.g., 2′-O-MS-TME-cGMP, EC₅₀ = 0.22 μM) highlight isoform-specific targeting .

Therapeutic Potential

Challenges

• Isoform Complexity: PDE2A exists in three splice variants (PDE2A1, A2, A3) with distinct subcellular localizations .

• Off-Target Effects: Cross-reactivity with other PDE isoforms necessitates rigorous antibody validation .